MiMedx Group
MDXGMiMedx is a biotechnology leader specializing in the development and commercialization of placental biologics and advanced healing solutions.
Earnings
Next report
Date not yet announcedFinancials
Q3 2026Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
Profile
MiMedx is a biotechnology leader specializing in the development and commercialization of placental biologics and advanced healing solutions. The company leverages proprietary processing technology to provide a portfolio of human-derived, animal-derived, and synthetic tissues designed to treat chronic wounds, burns, and surgical complications. Their core value proposition centers on reducing healthcare costs and improving patient outcomes through clinically-proven regenerative medicine.
A pioneer in placental biologics with a leading market position in amniotic tissue allografts and a first-mover advantage in the Japanese market.
FAQ
- What is MiMedx Group's market cap?
- MiMedx Group (MDXG) has a market capitalization of $579.3M and trades on NASDAQ.
- What is MiMedx Group's revenue and profitability?
- MiMedx Group generated $303.7M in trailing twelve-month revenue with a net loss of $19.2M, representing a net margin of -6.3%. Gross margin stands at 77.3%. The latest reported period is Q3 2026.
- Who are MiMedx Group's competitors?
- MiMedx Group's key competitors include Organogenesis Holdings Inc., Integra LifeSciences, SANUWAVE Health, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does MiMedx Group partner with?
- MiMedx Group's notable partners include Regenity Biosciences.
- Where is MiMedx Group headquartered?
- MiMedx Group is headquartered in United States of America and employs approximately 895 people. It has been publicly traded since 2007.
